Valo Health

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Valo Health headquartered in United States, North America, operates in the Information Technology, Biotechnology, Health Care, Medical sector. The company focuses on Information Technology and has secured $36.8B in funding across 80 round(s). With a team of 101-250 employees, Valo Health is actively contributing to advancements in Information Technology. Their latest funding round, Series C - Valo Health, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.